Economic evaluation of paroxetine and imipramine in depressed outpatients

Psychopharmacology Bulletin

Volumn 33, Issue 1, 1997, Pages 93-100

  Melton, Sarah T ^a   Kirkwood, Cynthia K ^a   Farrar, Travain W ^b   Brink, Douglas D ^c   Carroll, Norman V ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Revco Drug Stores Inc   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cost analysis; depression; imipramine; outpatients; paroxetine

Indexed keywords

IMIPRAMINE; PAROXETINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG COST; DRUG USE; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHILD; DEPRESSIVE DISORDER; FEMALE; HUMANS; IMIPRAMINE; MALE; MIDDLE AGED; OUTPATIENTS; PAROXETINE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0030936124     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bentkover, JD, and Feighner, JP. Cost analysis of paroxetine versus imipramine in major depression. Pharmacoeconomics 8(3):223-232, 1995.
2. Bignamini, A, and Rapisarda, V. A double-blind multicenter study of paroxetine and amitriptyline in depressed outpatients. Italian paroxetine study group. Int. Clin. Psychopharmacol. 6(Suppl. 4):37-41, 1992.
3. Caley, CF, and Weber, SS. Paroxetine: A selective serotonin reuptake inhibiting antidepressant. Ann. Pharmacother. 27:1212-1222, 1993.
4. Cohn, JB; Crowder, JE; Wilcox, CS; and Ryan, PJ. A placebo- and imipramine-controlled study of paroxetine. Psychopharmacol. Bull. 26(2):185-189, 1990.
5. Cohn, JB, and Wilcox, CS. Paroxetine in major depression: A double-blind trial with imipramine and placebo. J. Clin. Psychiatry 53(2, Suppl.):52-56, 1992.
6. Depression Guideline Panel. Depression in Primary Care: Vol. 2. Treatment of Major Depression. Clinical Practice Guideline, number 5. Rockville, MD. U.S. Department of Health and Human Services, Agency for Health Care Policy and Research. AHCPR Pub. No. 93-0551. April 1993.
7. De Wilde, J; Spiers, R; Mertens, C; Barthobme, F; Schotte, G; and Leyman, S. A double-blind, comparative multicentre study comparing paroxetine and fluoxetine in depressed patients. Acta Psychiatr. Scand. 87:141-145, 1993.
8. Dunbar, GC; Cohn, JB; Fabre, LF; Feighner, JP; Fieve, RR; Mendels, J; and Shrivastava, RK. A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br. J. Psychiatry 159:394-398, 1992.
9. Dunner, DL; Cohn, JB; Walshe, T; Cohn, CK; Feighner, JP; Fieve, RR; Halikas, JP; Hartford, JT; Hearst, ED; and Settle, EC. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J. Clin. Psychiatry 53(2, Suppl.):57-60, 1992.
10. Fabre, LF. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. J. Clin. Psychiatry 53(2, Suppl.):40-43, 1992.
11. Feighner, JP, and Boyer, WF. Paroxetine in the treatment of depression: A comparison with imipramine and placebo. Acta Psychiatr. Scand. Suppl. 350:125-129, 1989.
12. Feighner, JP; Cohn, JB; Fabre, LF; Fieve, RR; Mendels, J; Shrivastava, RK; and Dunbar, GC. A study comparing paroxetine, placebo and imipramine in depressed patients. J. Affect. Disord. 28:71-79, 1993.
13. Freemantle, N; House, A; Song, F; Mason, JM; and Sheldon, TA. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. Br. Med. J. 309:249-253, 1994.
14. Greenberg, PE; Stiglin, LE; Finkelstein, SN; and Berndt, ER. The economic burden of depression in 1990. J. Clin. Psychiatry 54(11):405-418, 1993.
15. Grimsley, SR, and Jann, MW. Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors. Clin. Pharm. 11:930-957, 1992.
16. Guillibert, E; Pelicier, Y; Archambault, JC; Chabannes, JP; Clerc, G; Desvilles, M; Guibert, M; Pagot, R; Poisat, JL; and Thobie, Y. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr. Scand. Suppl. 350:132-134, 1989.
17. Jönsson, B, and Bebbington, PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br. J. Psychiatry 164:665-673, 1994.
18. Kessler, RC; McGonagle, KA; Zhao, S; Nelson, CB; Hughes, M; Eshleman, S; Wittchen, HU; and Kendler, KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch. Gen. Psychiatry 51:8-19, 1994.
19. Lapierre, Y; Bentkover, J; Schainbaum, S; and Manners, S. Direct cost of depression: Analysis of treatment costs of paroxetine versus imipramine in Canada. Can. J. Psychiatry 40:370-377, 1995.
20. McFarland, BH. Cost-effectiveness considerations for managed care systems: Treating depression in primary care. Am. J. Med. 97(Suppl. 6A):47S-58S, 1994.
21. Peselow, ED; Filippi, AM; Goodnick, P; Barouche, F; and Fieve, RR. The short- and long-term efficacy of paroxetine HCl: Data from a 6-week double-blind parallel design trial vs. imipramine and placebo. Psychopharmacol. Bull. 25(2):267-271, 1989.
22. Psychopharmacology Bulletin. The value of psychiatric treatment: Its efficacy in severe mental disorders. Psychopharmacol. Bull. 29(4), 1994.
23. Sclar, DA; Robison, LM; Skaer, TL; Legg, RF; Nemec, NL; Galin, RS; Hughes, TE; and Buesching, DP. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization. Clin. Ther. 16(4):715-730, 1994.
24. Silver, JM; Yudofsky, SC; and Hurowitz, GI. Psychopharmacology and electroconvulsive therapy. In: Hales, RE; Yudofsky, SC; and Talbott, JA, eds. The American Psychiatric Press Textbook of Psychiatry, 2nd ed. Washington, DC: American Psychiatric Press, 1994; pp. 897-1007.
25. Sturm, R, and Wells, KB. How can care for depression become more cost-effective? JAMA 273(1):51-58, 1995.
26. Tignol, J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J. Clin. Psychopharmacol. 13(Suppl. 2):18S-22S, 1993.
27. Tulloch, IF, and Johnson, AM. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. J. Clin. Psychiatry 53(2, Suppl.):7-12, 1992.